0000899243-19-012052.txt : 20190503 0000899243-19-012052.hdr.sgml : 20190503 20190503172648 ACCESSION NUMBER: 0000899243-19-012052 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190501 FILED AS OF DATE: 20190503 DATE AS OF CHANGE: 20190503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lowrance David L CENTRAL INDEX KEY: 0001408498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 19797326 MAIL ADDRESS: STREET 1: 422 WILLIAM WALLACE DRIVE CITY: FRANKLIN STATE: TN ZIP: 37064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 512-614-1848 MAIL ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-01 0 0001160308 Savara Inc SVRA 0001408498 Lowrance David L 6836 BEE CAVE ROAD, BUILDING III SUITE 200 AUSTIN TX 78746 0 1 0 0 Chief Financial Officer Common Stock 2019-05-01 4 M 0 3800 1.51 A 3800 D Common Stock 2019-05-01 4 S 0 3800 10.7639 D 0 D Common Stock 2019-05-02 4 M 0 3700 1.51 A 3700 D Common Stock 2019-05-02 4 S 0 3700 10.8172 D 0 D Employee Stock Option (right to buy) 1.51 2019-05-01 4 M 0 3800 0.00 D 2026-10-25 Common Stock 3800 84384 D Employee Stock Option (right to buy) 1.51 2019-05-02 4 M 0 3700 0.00 D 2026-10-25 Common Stock 3700 80684 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 26, 2018. The price is a weighted average sale price. The sale prices ranged from $10.55 to $11.10. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The price is a weighted average sale price. The sale prices ranged from $10.68 to $11.02. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The shares subject to the option vest and become exercisable in sixteen equal installments on each quarterly anniversary of October 25, 2016, subject to the reporting person's continued service with Savara Inc. /s/ David Lowrance 2019-05-03